| Mitchell Heflin, MD | |
|
2100 Erwin Rd, Durham, NC 27710-0001 | |
| (919) 620-4467 | |
| Not Available |
| Full Name | Mitchell Heflin |
|---|---|
| Gender | Male |
| Speciality | Geriatric Medicine |
| Experience | 30 Years |
| Location | 2100 Erwin Rd, Durham, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558445619 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0300X | Internal Medicine - Geriatric Medicine | 96-00567 (North Carolina) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Duke University Hospital | Durham, NC | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Duke Health Integrated Practice Inc | 8325412737 | 2551 |
News Archive
Scientists at the University of North Carolina at Chapel Hill have created a new method of particle tracking based on machine learning that is far more accurate and provides better automation than techniques currently in use.
Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.
Four 18-year olds with stellar high school careers are heading off to university with some extra change in their pockets. The students have been named the 2009 recipients of The Canadian Medical Hall of Fame / Great-West Life, London Life and Canada Life Scholarship Award.
A multidisciplinary team of experts in heart failure, cardiac arrhythmia, and neurosurgery at The Mount Sinai Hospital are now testing nerve stimulation in the neck as a novel therapy for heart failure patients to potentially help relieve their debilitating symptoms of fatigue, shortness of breath, and heart arrhythmias, while reducing their hospitalizations.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products.
› Verified 6 days ago
| Entity Name | Private Diagnostic Clinic Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457389033 PECOS PAC ID: 1355254368 Enrollment ID: O20031204000577 |
News Archive
Scientists at the University of North Carolina at Chapel Hill have created a new method of particle tracking based on machine learning that is far more accurate and provides better automation than techniques currently in use.
Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.
Four 18-year olds with stellar high school careers are heading off to university with some extra change in their pockets. The students have been named the 2009 recipients of The Canadian Medical Hall of Fame / Great-West Life, London Life and Canada Life Scholarship Award.
A multidisciplinary team of experts in heart failure, cardiac arrhythmia, and neurosurgery at The Mount Sinai Hospital are now testing nerve stimulation in the neck as a novel therapy for heart failure patients to potentially help relieve their debilitating symptoms of fatigue, shortness of breath, and heart arrhythmias, while reducing their hospitalizations.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products.
› Verified 6 days ago
| Entity Name | The Forest At Duke Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548325111 PECOS PAC ID: 5991744518 Enrollment ID: O20050503000187 |
News Archive
Scientists at the University of North Carolina at Chapel Hill have created a new method of particle tracking based on machine learning that is far more accurate and provides better automation than techniques currently in use.
Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.
Four 18-year olds with stellar high school careers are heading off to university with some extra change in their pockets. The students have been named the 2009 recipients of The Canadian Medical Hall of Fame / Great-West Life, London Life and Canada Life Scholarship Award.
A multidisciplinary team of experts in heart failure, cardiac arrhythmia, and neurosurgery at The Mount Sinai Hospital are now testing nerve stimulation in the neck as a novel therapy for heart failure patients to potentially help relieve their debilitating symptoms of fatigue, shortness of breath, and heart arrhythmias, while reducing their hospitalizations.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products.
› Verified 6 days ago
| Entity Name | Duke Health Integrated Practice Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205553369 PECOS PAC ID: 8325412737 Enrollment ID: O20230327002247 |
News Archive
Scientists at the University of North Carolina at Chapel Hill have created a new method of particle tracking based on machine learning that is far more accurate and provides better automation than techniques currently in use.
Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.
Four 18-year olds with stellar high school careers are heading off to university with some extra change in their pockets. The students have been named the 2009 recipients of The Canadian Medical Hall of Fame / Great-West Life, London Life and Canada Life Scholarship Award.
A multidisciplinary team of experts in heart failure, cardiac arrhythmia, and neurosurgery at The Mount Sinai Hospital are now testing nerve stimulation in the neck as a novel therapy for heart failure patients to potentially help relieve their debilitating symptoms of fatigue, shortness of breath, and heart arrhythmias, while reducing their hospitalizations.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mitchell Heflin, MD 2100 Erwin Rd, Duke University Medical Center - Dumc 3003, Durham, NC 27710-0001 Ph: () - | Mitchell Heflin, MD 2100 Erwin Rd, Durham, NC 27710-0001 Ph: (919) 620-4467 |
News Archive
Scientists at the University of North Carolina at Chapel Hill have created a new method of particle tracking based on machine learning that is far more accurate and provides better automation than techniques currently in use.
Takeda Pharmaceutical Company Limited ("Takeda") and Takeda Global Research & Development Center, Inc., a wholly owned United States (U.S.) subsidiary, today jointly announced that the latter has received notification that the U.S. Food and Drug Administration (FDA) has agreed to the study design for a cardiovascular (CV) outcomes trial titled EXAMINE (EXamination of CArdiovascular OutcoMes: AlogliptIN vs. Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome) for alogliptin, a selective dipeptidyl peptidase IV inhibitor under investigation for the treatment of type 2 diabetes as an adjunct to diet and exercise.
Four 18-year olds with stellar high school careers are heading off to university with some extra change in their pockets. The students have been named the 2009 recipients of The Canadian Medical Hall of Fame / Great-West Life, London Life and Canada Life Scholarship Award.
A multidisciplinary team of experts in heart failure, cardiac arrhythmia, and neurosurgery at The Mount Sinai Hospital are now testing nerve stimulation in the neck as a novel therapy for heart failure patients to potentially help relieve their debilitating symptoms of fatigue, shortness of breath, and heart arrhythmias, while reducing their hospitalizations.
Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that the U.S. Food and Drug Administration (FDA) has approved ZORVOLEX™ (diclofenac) capsules, a nonsteroidal anti-inflammatory drug (NSAID), for the treatment of mild to moderate acute pain in adults. ZORVOLEX was approved at dosage strengths that are 20 percent lower than currently available diclofenac products.
› Verified 6 days ago
Dr. Stephen John Greene, M.D. Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 2301 Erwin Rd # Dumc3845, Durham, NC 27705 Phone: 919-684-8111 | |
Dr. Jacob Paul Feigal, M.D. Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: Duke University Hospital Gme, Box 3951, Durham, NC 27710 Phone: 919-684-8111 | |
Dr. David Keith Bright, MD, PHARM D Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 4205 Ben Franklin Blvd, Durham, NC 27704 Phone: 919-477-6900 Fax: 919-477-5081 | |
Yuri Anthony Fesko, MD Geriatric Medicine Medicare: Medicare Enrolled Practice Location: 4101 N Roxboro St, Durham, NC 27704 Phone: 919-684-8111 | |
Mary E Klotman, MD Geriatric Medicine Medicare: Not Enrolled in Medicare Practice Location: 40 Duke Medicine Cir, Durham, NC 27710 Phone: 919-684-8111 | |
Jonathan Paul Piccini Sr., M.D., M.H.S. Geriatric Medicine Medicare: Accepting Medicare Assignments Practice Location: 40 Duke Medicine Cir, Durham, NC 27710 Phone: 919-684-8111 | |
Dr. Deborah Anne Fisher, M.D. Geriatric Medicine Medicare: Not Enrolled in Medicare Practice Location: 508 Fulton St, Durham, NC 27705 Phone: 919-286-6945 |